Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nkarta stock | $62.54

Own Nkarta stock in just a few minutes.

Fact checked

Nkarta, Inc is a biotechnology business based in the US. Nkarta shares (NKTX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Nkarta

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Nkarta. Find the stock by name or ticker symbol: NKTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nkarta reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$62.54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Nkarta, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Nkarta. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Nkarta share price

Use our graph to track the performance of NKTX stocks over time.

Nkarta shares at a glance

Information last updated 2020-12-25.
Latest market closeUSD$62.54
52-week rangeUSD$22.46 - USD$79.16
50-day moving average USD$46.8294
200-day moving average USD$34.8205
Wall St. target priceUSD$73.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.8775

Buy Nkarta shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nkarta stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nkarta price performance over time

Historical closes compared with the close of $62.54 from 2020-12-18

1 week (2021-01-07) 12.68%
1 month (2020-12-17) -7.35%
3 months (2020-10-15) 100.64%
6 months (2020-07-15) 71.11%
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Nkarta financials

Revenue TTM USD$385
Gross profit TTM USD$-17,101,570
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$2.3 billion

TTM: trailing 12 months

Shorting Nkarta shares

There are currently 1.0 million Nkarta shares held short by investors – that's known as Nkarta's "short interest". This figure is 5.3% up from 967,582 last month.

There are a few different ways that this level of interest in shorting Nkarta shares can be evaluated.

Nkarta's "short interest ratio" (SIR)

Nkarta's "short interest ratio" (SIR) is the quantity of Nkarta shares currently shorted divided by the average quantity of Nkarta shares traded daily (recently around 140552.55172414). Nkarta's SIR currently stands at 7.25. In other words for every 100,000 Nkarta shares traded daily on the market, roughly 7250 shares are currently held short.

However Nkarta's short interest can also be evaluated against the total number of Nkarta shares, or, against the total number of tradable Nkarta shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nkarta's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Nkarta shares in existence, roughly 30 shares are currently held short) or 0.034% of the tradable shares (for every 100,000 tradable Nkarta shares, roughly 34 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nkarta.

Find out more about how you can short Nkarta stock.

Nkarta share dividends

We're not expecting Nkarta to pay a dividend over the next 12 months.

Nkarta overview

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site